16 reports

Head and neck cancer

4385 5000 3900
  • Product profile (late stage): Reolysin

Activation of the Ras pathway inhibits double-stranded RNA-activated protein kinase and eIF##-alpha phosphorylation which results in viral accumulation inside cancer cells (Carew et al., 2013).

  • Ear, Nose, And Throat Medicine
  • United States
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.

Researchers are using automated solutions to isolate RNA and DNA from minuscule tissue samples.

  • Ear, Nose, And Throat Medicine
  • Magnetic Resonance Imaging
  • United States
  • GE Healthcare Limited
  • Varian Medical Systems, Inc.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Infectious Disease
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

Merck KG ## ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## ## Merck & Co Inc ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## Bristol-Myers Squibb Co ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## Eli Lilly and Co ## ## ## ##

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Lung Cancer
  • World
  • Merck & Co., Inc.

Peak mean/ median antibody responses to HPV## E## and HPV## E## antigens for ## evaluable pts were ##:##/ ##:## and ##:##/ ##:##, respectively.

  • Ear, Nose, And Throat Medicine
  • Medical Biotechnology
  • Sexually Transmitted Disease
  • Therapy
  • Inovio Pharmaceuticals, Inc.
  • Official Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Merck KG ## ## ## ## ## ## ## C.

  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • United States
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Ear, Nose, And Throat Medicine
  • Targeted Therapy
  • Therapy
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

Boehringer Sohn AG & Co KG ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## E.

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • World
  • Bristol-Myers Squibb Company
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • United States
  • World
  • Clinical Trial profile. 22 Trial Title

The prominent features of this report are - ##.

  • Ear, Nose, And Throat Medicine
  • Health Services
  • Infectious Disease
  • World
  • Product Initiative

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • United States
  • World

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Drug Development
  • Ear, Nose, And Throat Medicine
  • Pharmaceutical
  • World

CHAPTER OUTLINES ##. ##.

  • Ear, Nose, And Throat Medicine
  • United States
  • AudioCure Pharma GmbH
  • Autifony Therapeutics Limited
  • Cochlear Limited
  • SMALL MOLECULES TO INHIBIT 16S RRNA FOR HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA AND ORAL CANCER - DRUG PROFILE
  • ANTISENSE OLIGONUCLEOTIDE TO TARGET EGFR FOR HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA - DRUG PROFILE

Pactamycin analogs are ##S RNA inhibitors.

  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • United States
  • Company
  • Product Initiative
  • Symptoms of Head and Neck Cancer Metastasis, 2017
  • Head and Neck Cancer, Key Features and Pipeline Activity of Protein Kinase C Epsilon, 2017

One study found that RNA interference knockdown of PKC epsilon in two highly invasive and motile HNC cell lines with elevated endogenous PKC epsilon levels resulted in cells that were significantly less invasive and motile (Pan et al., 2006).

  • Cancer
  • Ear, Nose, And Throat Medicine
  • Health Services
  • Healthcare
  • Therapy
  • HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA - PIPELINE BY GENESEGUES INC, H2 2016
  • HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA - PIPELINE BY BIONTECH AG, H2 2016

All three resected patient tumors contained wild-type reovirus RNA and protein.

  • Ear, Nose, And Throat Medicine
  • Monoclonal Antibody
  • United States
  • Company
  • Product Initiative